These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 9815786

  • 1. Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies.
    Goss PE, Reid CL, Bailey D, Dennis JW.
    Clin Cancer Res; 1997 Jul; 3(7):1077-86. PubMed ID: 9815786
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of swainsonine in patients with advanced malignancies.
    Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW.
    Cancer Res; 1994 Mar 15; 54(6):1450-7. PubMed ID: 8137247
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 6. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.
    Eur J Haematol; 2008 Sep 15; 81(3):170-6. PubMed ID: 18510700
    [Abstract] [Full Text] [Related]

  • 7. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW.
    Clin Cancer Res; 2005 Nov 01; 11(21):7866-71. PubMed ID: 16278410
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS.
    J Clin Oncol; 2006 Sep 01; 24(25):4092-9. PubMed ID: 16943527
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN.
    Clin Cancer Res; 2006 Feb 15; 12(4):1251-9. PubMed ID: 16489081
    [Abstract] [Full Text] [Related]

  • 12. Growth inhibition of human melanoma tumor xenografts in athymic nude mice by swainsonine.
    Dennis JW, Koch K, Yousefi S, VanderElst I.
    Cancer Res; 1990 Mar 15; 50(6):1867-72. PubMed ID: 2106389
    [Abstract] [Full Text] [Related]

  • 13. Inhibitors of carbohydrate processing: A new class of anticancer agents.
    Goss PE, Baker MA, Carver JP, Dennis JW.
    Clin Cancer Res; 1995 Sep 15; 1(9):935-44. PubMed ID: 9816064
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M, Mita A, Sarantopoulos J, Takimoto CH, Rowinsky EK, Romero O, Angiuli P, Allievi C, Eisenfeld A, Verschraegen CF.
    Cancer Chemother Pharmacol; 2009 Jul 15; 64(2):287-95. PubMed ID: 19034451
    [Abstract] [Full Text] [Related]

  • 15. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.
    Clin Cancer Res; 2000 Apr 15; 6(4):1259-66. PubMed ID: 10778949
    [Abstract] [Full Text] [Related]

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 15; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 17. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.
    Clin Cancer Res; 2001 Dec 15; 7(12):3912-9. PubMed ID: 11751482
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.